TCGX Raised $600 Million for Asian Biotech Fund
The firm expanded its reach into Asia by opening new offices in Shanghai and Hong Kong to target regional innovation.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Is now a good time for firms to increase investment in international biotechnology research?
TCGX has successfully raised $600 million for its inaugural Asia Life Sciences Fund I to invest in regional biotechnology companies. The firm is applying its established investment strategies from Western markets to accelerate the development of competitive Asian biotech innovation.
Why it matters
The move reflects the firm's strategic identification of Asia as an increasingly vital hub for global biotechnology breakthroughs. By establishing a local presence, TCGX aims to capitalize on new innovation pipelines that complement its existing global investment portfolio.
The new $600 million Asia fund operates in synergy with TCGX's $3.1 billion total capital base. The firm previously raised $824 million for its first fund in 2021 and has a track record of backing high-value exits, including the $446 million ADARx IPO.
The players
TCGX
This venture capital firm specializes in life sciences and biotechnology investments.
Dandan Dong
She serves as the managing partner overseeing all TCGX investment activities in the Asian market.
Roche
This multinational healthcare company is a major player in the global pharmaceutical industry.
Novartis
This global pharmaceutical corporation focuses on developing innovative medicine and medical treatments.
Bristol Myers Squibb
This company is a global biopharmaceutical entity that focuses on discovering and developing life-saving medicines.
The details
TCGX is leveraging its proven Western investment playbook to identify and support high-growth biotech startups in China and the broader Asian market. The firm has opened dedicated offices in Shanghai and Hong Kong to oversee these operations and maintain closer ties to regional research institutions.
Timeline
TCGX raised its first fund of $824 million in 2021.
Roche and Bristol Myers Squibb acquired portfolio companies in late 2023.
Dandan Dong joined the firm to lead Asian operations in 2024.
Novartis acquired Tourmaline Bio for $1.4 billion in 2025.
ADARx Pharmaceuticals completed its $446 million IPO in September 2026.
The Tech Race
This fund expansion marks a significant step in the global race for biotech intellectual property, mirroring the high-stakes momentum seen in recent successful pharmaceutical acquisitions. It positions TCGX to compete directly with other global investors by securing early access to emerging Asian innovation.
For investors and industry followers, this move signals a shifting focus toward Asian biotech that may alter the landscape of drug development and clinical trials. Increased capital inflow could lead to faster commercialization of new medical therapies for patients globally.
The takeaway
The successful capital raise highlights the growing professionalization and financial integration of the Asian biotech sector with global markets. Investors should monitor how the cross-border application of investment playbooks affects the speed of pharmaceutical innovation.
Further reading
Learn more about the latest industry trends on our Biotech section page.
Live Poll
Is now a good time for firms to increase investment in international biotechnology research?
